# Oruka Therapeutics, Inc. (ORKA) stock: price and valuation

URL: https://funkfolio.com/stock/ORKA

> Oruka Therapeutics, Inc. (ORKA) trades at $96.75 and is worth $6.56B. Valuation against its own history and up to 20 years of financials.

---

## Oruka Therapeutics, Inc. (ORKA)

Oruka Therapeutics, Inc. (ORKA) is a healthcare company (biotechnology) based in the United States. The share price is $96.75, down 2.51% on the day, which values the company at $6.56B. Price as of 17 Nov 2026, 19:21 UTC, from Yahoo Finance.

### Key facts

- **Share price:** $96.75 −2.51% today
- **Market value:** $6.56B
- **200-week average:** $34.15 183% above
- **Sector:** Healthcare

Figures as of 17 Nov 2026, 19:21 UTC. Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

### Oruka Therapeutics, Inc. in more detail

ORKA trades at -33.8× next year's expected earnings. It sits 183% above its 200-week average of $34.15.

In its favour: More cash than debt. Worth checking: Share count keeps rising.

3 of the superinvestors tracked here hold ORKA, including Peter Kolchinsky (1.3% of the portfolio), Andreas Halvorsen (0.4% of the portfolio), Polen Capital team (0.0% of the portfolio).

### Superinvestors holding ORKA

3 of the investors tracked here report a position in their latest 13F filing.

- [Peter Kolchinsky RA Capital Management](https://funkfolio.com/gurus/peter-kolchinsky) 1.29% of portfolio · $148M · new · Q2 2026
- [Andreas Halvorsen Viking Global Investors](https://funkfolio.com/gurus/andreas-halvorsen) 0.41% of portfolio · $143.1M · trimmed · Q2 2026
- [Polen Capital team Polen Capital Management](https://funkfolio.com/gurus/polen-capital) 0.03% of portfolio · $3M · new · Q3 2026

### Health Care companies of similar size

- [Bausch + Lomb BLCO](https://funkfolio.com/stock/BLCO)
- [Amneal Pharmaceuticals AMRX](https://funkfolio.com/stock/AMRX)
- [Caris Life Sciences CAI](https://funkfolio.com/stock/CAI)
- [Immunovant IMVT](https://funkfolio.com/stock/IMVT)
- [Axsome Therapeutics AXSM](https://funkfolio.com/stock/AXSM)
- [Chemed CHE](https://funkfolio.com/stock/CHE)
- [Arrowhead Pharmaceuticals ARWR](https://funkfolio.com/stock/ARWR)
- [MSA Safety MSA](https://funkfolio.com/stock/MSA)
- [CG Oncology CGON](https://funkfolio.com/stock/CGON)
- [Kodiak Sciences KOD](https://funkfolio.com/stock/KOD)
- [Lantheus Holdings LNTH](https://funkfolio.com/stock/LNTH)
- [RadNet RDNT](https://funkfolio.com/stock/RDNT)

Side by side: [ORKA vs CHE (Oruka Therapeutics, Inc. vs Chemed)](https://funkfolio.com/compare/che-vs-orka) [ORKA vs AXSM (Oruka Therapeutics, Inc. vs Axsome Therapeutics)](https://funkfolio.com/compare/axsm-vs-orka) [ORKA vs ARWR (Oruka Therapeutics, Inc. vs Arrowhead Pharmaceuticals)](https://funkfolio.com/compare/arwr-vs-orka) [ORKA vs MSA (Oruka Therapeutics, Inc. vs MSA Safety)](https://funkfolio.com/compare/msa-vs-orka) [ORKA vs IMVT (Oruka Therapeutics, Inc. vs Immunovant)](https://funkfolio.com/compare/imvt-vs-orka)

[All health care companies by market value](https://funkfolio.com/companies/sector/health-care) [Largest companies in the United States](https://funkfolio.com/companies/country/united-states) [All stocks A–Z](https://funkfolio.com/stocks)

### Oruka Therapeutics, Inc. (ORKA): questions and answers

**What is Oruka Therapeutics, Inc.'s market cap?**

Oruka Therapeutics, Inc. is valued at $6.56B at a share price of $96.75.

**Is ORKA above its 200-week moving average?**

Yes. ORKA is 183.3% above its 200-week average of $34.15. Long-term investors watch that line because strong companies rarely trade below it for long.

**Does ORKA pay a dividend?**

Oruka Therapeutics, Inc. does not currently pay a regular dividend.

**Which famous investors own ORKA?**

In their latest quarterly filings, Peter Kolchinsky (1.3% of the portfolio), Andreas Halvorsen (0.4% of the portfolio), Polen Capital team (0.0% of the portfolio) hold ORKA. These filings are published up to 45 days after each quarter ends, so positions may have changed since.

### Learn to read these numbers

[All stocks guides →](https://funkfolio.com/learn/stocks)

- [Altman Z-score: formula, zones and where it fails](https://funkfolio.com/learn/stocks/altman-z-score)

  The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- [Analyst price targets and ratings: what they mean](https://funkfolio.com/learn/stocks/analyst-price-targets)

  An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- [Free cash flow and FCF yield explained](https://funkfolio.com/learn/stocks/free-cash-flow)

  Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.

### Cite this page

Funkfolio, “Oruka Therapeutics, Inc. (ORKA) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/ORKA

Underlying data: Yahoo Finance; company filings with the SEC.
